Related Experiment Video

Updated: Jun 2, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas

Elias Drakos1, George Z Rassidakis, L Jeffrey Medeiros

  • 1Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

Expert Reviews in Molecular Medicine
|February 5, 2008
PubMed

Insights

The mammalian target of rapamycin (mTOR) pathway regulates cell growth and is crucial in cancer. Inhibiting mTOR shows promise for treating lymphomas, with early clinical trials yielding encouraging results.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • The mammalian target of rapamycin (mTOR) is a key regulator of cell growth, survival, and proliferation.
  • mTOR signaling is influenced by pathways like AKT and ERK/MAPK.
  • Dysregulation of mTOR is implicated in cancer, affecting cell cycle, apoptosis, and drug resistance.

Purpose of the Study:

  • To explore the role of the mTOR pathway in lymphoma biology.
  • To review the therapeutic potential of mTOR inhibitors in treating lymphomas.
  • To highlight the significance of understanding mTOR regulation for developing targeted lymphoma therapies.

Main Methods:

  • Review of in vitro and in vivo studies on the mTOR pathway in lymphomas.
  • Analysis of clinical trial data for mTOR inhibitors in lymphoma patients.
  • Examination of the effects of mTOR inhibition on malignant cells.

Main Results:

  • mTOR plays a significant role in the biology of malignant cells, contributing to cell cycle deregulation, apoptosis resistance, and chemotherapy resistance.
  • mTOR inhibitors, including rapamycin derivatives like temsirolimus, have demonstrated anti-tumor effects in various neoplasms, including lymphomas.
  • Preliminary clinical trials show encouraging responses in lymphoma patients, particularly mantle cell lymphoma, treated with mTOR inhibitors.

Conclusions:

  • Understanding mTOR regulation is vital for unraveling lymphomagenesis.
  • Targeted therapies inhibiting the mTOR pathway hold significant potential for improving lymphoma treatment outcomes.
  • Further research into mTOR pathways can lead to the development of more effective and precise therapies for lymphoma patients.

More Related Videos

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...